

Kimme L Hyrich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1553502/publications.pdf>

Version: 2024-02-01

239
papers

10,853
citations

26567

56
h-index

37111

96
g-index

240
all docs

240
docs citations

240
times ranked

10649
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on" Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e114-e114.	0.5	2
2	Response to: "Correspondence on" Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Mulhearn <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e116-e116.	0.5	87
3	Response to: "Correspondence on" Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Rosenbaum <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e139-e139.	0.5	2
4	"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry" by Gianfrancesco <i>et al</i> . Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases" by Giollo <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e223-e223.	0.5	5
5	Burden of comorbid conditions in children and young people with juvenile idiopathic arthritis: a collaborative analysis of 3 JIA registries. <i>Rheumatology</i> , 2022, 61, 2524-2534.	0.9	9
6	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 20-33.	0.5	104
7	SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 145-150.	0.5	30
8	How effective are JAK-inhibitors? Perspectives from clinical trials and real-world studies. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 207-220.	1.3	5
9	COVID-19 in Pregnant Women With Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance. <i>Journal of Rheumatology</i> , 2022, 49, 110-114.	1.0	9
10	Incidence and prevalence of juvenile idiopathic arthritis in the United Kingdom, 2000"2018: results from the Clinical Practice Research Datalink. <i>Rheumatology</i> , 2022, 61, 2548-2554.	0.9	21
11	Juvenile idiopathic arthritis. <i>Nature Reviews Disease Primers</i> , 2022, 8, 5.	18.1	90
12	No evidence that genetic predictors of susceptibility predict changes in core outcomes in JIA. <i>Rheumatology</i> , 2022, , .	0.9	0
13	Biologic and advanced therapy registers in rheumatoid arthritis. <i>Medicine</i> , 2022, , .	0.2	0
14	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 780-785.	0.5	12
15	Rates and predictors of methotrexate-related adverse events in patients with early rheumatoid arthritis: results from a nationwide UK study. <i>Rheumatology</i> , 2022, 61, 3930-3938.	0.9	13
16	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 695-709.	0.5	130
17	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.5	49
18	Exploring the disparity between inflammation and disability in the 10-year outcomes of people with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 4687-4701.	0.9	5

#	ARTICLE	IF	CITATIONS
19	Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 998-1005.	0.5	12
20	Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 4678-4686.	0.9	10
21	Pre-defined gene co-expression modules in rheumatoid arthritis transition towards molecular health following anti-TNF therapy. <i>Rheumatology</i> , 2022, 61, 4935-4944.	0.9	3
22	The Role of Age in Delays to Rheumatological Care in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2022, 49, 1037-1041.	1.0	2
23	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	1.8	34
24	P090â€fClinical prediction models for methotrexate treatment outcomes in rheumatoid arthritis patients: a review of existing models and summary of their limitations. <i>Rheumatology</i> , 2022, 61, .	0.9	0
25	OA14â€fOutcomes after switching from etanercept originator to its biosimilar (SB4) for the treatment of rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	0
26	P200â€fCombining protein quantitative trait and genetic risk score analysis to identify biomarkers of treatment response to TNFi in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	0
27	OA14bâ€fEtanercept originator versus its biosimilar (SB4) for the treatment of rheumatoid arthritis. Are they truly similar?. <i>Rheumatology</i> , 2022, 61, .	0.9	0
28	OA21â€fContinuing specialist care beyond age 16 in young people with juvenile idiopathic arthritis: a descriptive study using electronic health records in England. <i>Rheumatology</i> , 2022, 61, .	0.9	0
29	P068â€fMonitoring of methotrexate blood toxicity during the COVID-19 pandemic for patients with rheumatoid arthritis: data from the Greater Manchester Care Record. <i>Rheumatology</i> , 2022, 61, .	0.9	0
30	OA19â€fSuccesses and challenges in harmonising four national juvenile idiopathic arthritis cohorts: an example from CLUSTER consortium. <i>Rheumatology</i> , 2022, 61, .	0.9	1
31	OA01â€fSafety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Rheumatology</i> , 2022, 61, .	0.9	0
32	OA24â€fPredicting drug immunogenicity to tumour necrosis factor inhibitors in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	0
33	OA15â€fDrivers of change in four and two component disease activity scores after etanercept treatment, in a multi-centre cohort of patients with established rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	0
34	P189â€fA longitudinal study of psychological predictors of response to adalimumab in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, .	0.9	1
35	P162â€fSocio-economic status in patients with juvenile idiopathic arthritis in the United Kingdom. <i>Rheumatology</i> , 2022, 61, .	0.9	0
36	OA16â€fTherapeutic certolizumab pegol drug levels to achieve good EULAR response in patients with rheumatoid arthritis: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS) cohort. <i>Rheumatology</i> , 2022, 61, .	0.9	0

#	ARTICLE	IF	CITATIONS
37	Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the "JAK-pot" collaboration. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1358-1366.	0.5	48
38	Common Functional Ability Score for Young People With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 947-954.	1.5	2
39	Response to: "Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis" by Gyrfi et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e88-e88.	0.5	8
40	Translating research into clinical practice: quality improvement to halve non-adherence to methotrexate. <i>Rheumatology</i> , 2021, 60, 125-131.	0.9	6
41	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.5	224
42	Changes in the illness perceptions of patients with rheumatoid arthritis over the first year of methotrexate therapy. <i>Rheumatology</i> , 2021, 60, 2355-2365.	0.9	11
43	Patient-reported wellbeing and clinical disease measures over time captured by multivariate trajectories of disease activity in individuals with juvenile idiopathic arthritis in the UK: a multicentre prospective longitudinal study. <i>Lancet Rheumatology</i> , The, 2021, 3, e111-e121.	2.2	23
44	Rheumatic disease and COVID-19: epidemiology and outcomes. <i>Nature Reviews Rheumatology</i> , 2021, 17, 71-72.	3.5	120
45	Do people with rheumatoid arthritis maintain their physical activity level at treatment onset over the first year of methotrexate therapy?. <i>Rheumatology</i> , 2021, 60, 4633-4642.	0.9	5
46	Prediction of response of methotrexate in patients with rheumatoid arthritis using serum lipidomics. <i>Scientific Reports</i> , 2021, 11, 7266.	1.6	21
47	Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment. <i>Arthritis Research and Therapy</i> , 2021, 23, 80.	1.6	11
48	Baseline predictors of methotrexate-related adverse events in methotrexate-naïve patients with RA. <i>Rheumatology</i> , 2021, 60, .	0.9	0
49	Serious infection with tocilizumab compared to TNF-inhibitors and other bDMARDs in rheumatoid arthritis patients: does line of therapy matter?. <i>Rheumatology</i> , 2021, 60, .	0.9	0
50	Demyelinating Events Following Initiation of Anti-TNF± Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	3.1	16
51	Prevalence and predictors of adverse events with methotrexate mono- and combination-therapy for rheumatoid arthritis: a systematic review. <i>Rheumatology</i> , 2021, 60, 4001-4017.	0.9	17
52	EULAR COVID-19 registry: lessons learnt and future considerations. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1110-1115.	0.5	6
53	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.5	151
54	Nothing about us without us: involving patient collaborators for machine learning applications in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1505-1510.	0.5	9

#	ARTICLE	IF	CITATIONS
55	Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1800-1809.	2.9	18
56	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.5	496
57	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	2.8	86
58	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e855-e864.	2.2	38
59	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. <i>RMD Open</i> , 2021, 7, e001818.	1.8	4
60	The predictors of and reasons for non-adherence in an observational cohort of patients with rheumatoid arthritis commencing methotrexate. <i>Rheumatology</i> , 2020, 59, 213-223.	0.9	22
61	The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data. <i>Rheumatology</i> , 2020, 59, 1391-1397.	0.9	12
62	Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 1364-1371.	0.9	43
63	Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as "satisfactory". <i>Rheumatology</i> , 2020, 59, 1853-1861.	0.9	8
64	What can rheumatology expect from real-world data?. <i>Rheumatology</i> , 2020, 59, 12-13.	0.9	1
65	Early response to anti-TNF predicts long-term outcomes including sustained remission: an analysis of the BSRBR-RA. <i>Rheumatology</i> , 2020, 59, 1709-1714.	0.9	8
66	P212 The effect of body weight in response to subcutaneous tocilizumab in patients with RA. <i>Rheumatology</i> , 2020, 59, .	0.9	0
67	P228 Risk of sinusitis in patients with rheumatoid arthritis: association with different treatment strategies. <i>Rheumatology</i> , 2020, 59, .	0.9	0
68	O27 Early experience with JAK inhibitor prescribing in the UK: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). <i>Rheumatology</i> , 2020, 59, .	0.9	1
69	Harnessing repeated measurements of predictor variables for clinical risk prediction: a review of existing methods. <i>Diagnostic and Prognostic Research</i> , 2020, 4, 9.	0.8	20
70	COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: "Correspondence on Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry" by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials: a real-world district general hospital experience" by K. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-218713.	0.5	11
71	Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach. <i>Drugs</i> , 2020, 80, 849-857.	4.9	20
72	Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs. <i>Arthritis and Rheumatology</i> , 2020, 72, 1632-1642.	2.9	9

#	ARTICLE	IF	CITATIONS
73	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866.	0.5	908
74	Frequency of biologic switching and the outcomes of switching in children and young people with juvenile idiopathic arthritis: a national cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e217-e226.	2.2	25
75	Predictors of presenteeism, absenteeism and job loss in patients commencing methotrexate or biologic therapy for rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 2908-2919.	0.9	17
76	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , The, 2020, 2, e250-e253.	2.2	172
77	Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. <i>Pharmacogenomics</i> , 2020, 21, 1151-1156.	0.6	3
78	Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2019, 58, 80-85.	0.9	33
79	Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra. <i>Rheumatology</i> , 2019, 58, 94-102.	0.9	20
80	Cervical screening uptake and rates of cervical dysplasia in the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2019, 59, 559-567.	0.9	1
81	A UK study: vocational experiences of young adults with juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2019, 17, 54.	0.9	0
82	O19 The association of biologic drug-levels with infection risk: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). <i>Rheumatology</i> , 2019, 58, .	0.9	0
83	O23 Using big data in the design and validation of a simulation of the healthcare system for patients with inflammatory rheumatic disease: results from the SiMSK study. <i>Rheumatology</i> , 2019, 58, .	0.9	0
84	O24 The impact of early referral and lowering clinical thresholds of biologic access on the disease course and costs in RA: results from the SiMSK study. <i>Rheumatology</i> , 2019, 58, .	0.9	0
85	Predicting disease outcomes in juvenile idiopathic arthritis: challenges, evidence, and new directions. <i>The Lancet Child and Adolescent Health</i> , 2019, 3, 725-733.	2.7	23
86	Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data. <i>Rheumatology</i> , 2019, 58, 1168-1175.	0.9	13
87	Predictors, demographics and frequency of sustained remission and low disease activity in anti-tumour necrosis factor treated rheumatoid arthritis patients. <i>Rheumatology</i> , 2019, 58, 2162-2169.	0.9	26
88	Predicting Remission Remains a Challenge in Patients with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 552-554.	1.0	5
89	Not all moderate disease is the same – Identification of disability trajectories among patients with rheumatoid arthritis and moderate disease activity. <i>PLoS ONE</i> , 2019, 14, e0215999.	1.1	13
90	Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2019, 58, 1767-1776.	0.9	24

#	ARTICLE	IF	CITATIONS
91	Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2019, 58, 1453-1458.	0.9	11
92	SAT0062â€¦STRATIFIED MEDICINE FOR RHEUMATOID ARTHRITIS: PREDICTING RESPONSE TO BIOLOGIC THERAPY USING IMMUNE CELL SIGNATURES. , 2019, , .		0
93	FRI0674â€¦THE ASSOCIATION BETWEEN JOINT EROSIONS PLUS AUTOANTIBODY POSITIVITY AT INITIATION OF METHOTREXATE OR BIOLOGIC THERAPY FOR RHEUMATOID ARTHRITIS AND DISEASE ACTIVITY AND DISABILITY OVER ONE YEAR. , 2019, , .		0
94	SAT0141â€¦FREQUENCY AND REASONS FOR SWITCHING BACK TO BIOLOGIC ORIGINATOR FOLLOWING INITIAL SWITCH TO BIOLOGIC BIOSIMILAR. , 2019, , .		0
95	AB0434â€¦EARLY EXPERIENCE WITH JAK INHIBITOR PRESCRIBING IN THE UK: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS (BSRBR-RA). , 2019, , .		1
96	FRI0546â€¦TRAJECTORIES OF DISEASE ACTIVITY OVER THE FIRST THREE YEARS FOLLOWING JUVENILE IDIOPATHIC ARTHRITIS DIAGNOSIS. , 2019, , .		0
97	THU0668â€¦THE ASSOCIATION BETWEEN ANTI-CCP TITRE LEVEL AND DISEASEACTIVITY AND DISABILITY OVER ONE YEAR FOLLOWING THE INITIATION OF METHOTREXATE OR BIOLOGIC THERAPY FOR ANTI-CCP+ RHEUMATOID ARTHRITIS. , 2019, , .		0
98	Real world data in rheumatology. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, S22-S24.	1.6	5
99	Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?. <i>Current Opinion in Rheumatology</i> , 2019, 31, 285-292.	2.0	39
100	Profiling of Gene Expression Biomarkers as a Classifier of Methotrexate Nonresponse in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 678-684.	2.9	50
101	Use and effectiveness of rituximab in children and young people with juvenile idiopathic arthritis in a cohort study in the United Kingdom. <i>Rheumatology</i> , 2019, 58, 331-335.	0.9	27
102	Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2018, 57, 997-1001.	0.9	82
103	Long-term Outcomes Following Achievement of Clinically Inactive Disease in Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1519-1529.	2.9	28
104	The relationship between depression and biologic treatment response in rheumatoid arthritis: An analysis of the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2018, 57, 835-843.	0.9	83
105	Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register. <i>RMD Open</i> , 2018, 4, e000596.	1.8	38
106	The influence of TNF inhibitors on dementia incidence in patients with rheumatoid arthritis; an analysis from the BSRBRâ€¦RA. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 556-558.	1.3	13
107	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 476-479.	0.5	47
108	O86â€¦A longitudinal analysis of prevalence of sustained remission and low disease activity in rheumatoid arthritis patients treated with anti-tumour necrosis factor: an analysis of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2018, 57, .	0.9	0

#	ARTICLE	IF	CITATIONS
109	Depressive symptoms, pain and disability for adolescent patients with juvenile idiopathic arthritis: results from the Childhood Arthritis Prospective Study. <i>Rheumatology</i> , 2018, 57, 1381-1389.	0.9	52
110	Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrhumdis-2017-212825.	0.5	115
111	Long-term persistence with rituximab in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, 1089-1096.	0.9	22
112	The prioritization of symptom beliefs over illness beliefs: The development and validation of the Pain Perception Questionnaire for Young People. <i>British Journal of Health Psychology</i> , 2018, 23, 68-87.	1.9	14
113	Patterns of pain over time among children with juvenile idiopathic arthritis. <i>Archives of Disease in Childhood</i> , 2018, 103, 437-443.	1.0	45
114	Growth patterns in early juvenile idiopathic arthritis: Results from the Childhood Arthritis Prospective Study (CAPS). <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 53-60.	1.6	26
115	Malignancy and rheumatoid arthritis: Epidemiology, risk factors and management. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 869-886.	1.4	73
116	P41â€fA UK study: vocational experiences of young adults with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2018, 57, .	0.9	0
117	227â€fPredictors of presenteeism and absenteeism in patients commencing treatment with methotrexate monotherapy or biologic therapy for rheumatoid arthritis. <i>Rheumatology</i> , 2018, 57, .	0.9	0
118	e11â€fPatterns of the patient acceptable symptom state over 12 months following the initiation of methotrexate therapy in patients with rheumatoid arthritis, and the association between these patterns and disability and disease activity. <i>Rheumatology</i> , 2018, 57, .	0.9	0
119	P33â€fFirst diagnosis of uveitis is not higher among juvenile idiopathic arthritis patients receiving etanercept compared to methotrexate. <i>Rheumatology</i> , 2018, 57, .	0.9	0
120	O89â€fThe association between poor prognostic factors at methotrexate initiation and disease activity and disability over one year: results from the Rheumatoid Arthritis Medication Study. <i>Rheumatology</i> , 2018, 57, .	0.9	0
121	212â€fMultimorbidity is associated with increased disability but lower disease activity over time in patients with RA: results from the BSRBR-RA. <i>Rheumatology</i> , 2018, 57, .	0.9	0
122	296â€fUK survey of young adults with juvenile idiopathic arthritis and their vocational experiences. <i>Rheumatology</i> , 2018, 57, .	0.9	0
123	e12â€fClinical phenotypes of patients with rheumatoid arthritis who identify as in a patient acceptable symptom state at methotrexate initiation and a comparison of the outcome of these phenotypes over 12 months. <i>Rheumatology</i> , 2018, 57, .	0.9	0
124	Update on the epidemiology, risk factors and disease outcomes of Juvenile idiopathic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 206-222.	1.4	47
125	Prevalence and course of lower limb disease activity and walking disability over the first 5 years of juvenile idiopathic arthritis: results from the childhood arthritis prospective study. <i>Rheumatology Advances in Practice</i> , 2018, 2, rky039.	0.3	11
126	243â€fLongâ€fTerm risk of serious infections in patients with rheumatoid arthritis treated with rituximab: five year data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBRâ€fRA). <i>Rheumatology</i> , 2018, 57, .	0.9	0

#	ARTICLE	IF	CITATIONS
127	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1705-1709.	0.5	83
128	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2018, 18, 657-664.	0.9	41
129	Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1405-1412.	0.5	117
130	Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS). <i>Arthritis Research and Therapy</i> , 2018, 20, 147.	1.6	73
131	Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2018, 57, 1533-1540.	0.9	20
132	OPredicting remission from one year following initial presentation in a multicentre inception cohort of patients with juvenile idiopathic arthritis. <i>Rheumatology</i> , 2018, 57, .	0.9	0
133	Does sex or ethnicity impact anti-tumour necrosis factor agent use in rheumatoid arthritis?. <i>Rheumatology</i> , 2017, 56, kew466.	0.9	0
134	Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 654-660.	0.5	122
135	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 208-213.	0.5	49
136	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 386-391.	0.5	150
137	Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 497-503.	0.5	88
138	Drug-specific risk and characteristics of lupus and vasculitis-like events in patients with rheumatoid arthritis treated with TNFi: results from BSRBR-RA. <i>RMD Open</i> , 2017, 3, e000314.	1.8	29
139	How common is clinically inactive disease in a prospective cohort of patients with juvenile idiopathic arthritis? The importance of definition. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1381-1388.	0.5	42
140	Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 241-250.	1.0	40
141	How common is remission in juvenile idiopathic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 331-337.	1.6	60
142	Biologics registers in RA: methodological aspects, current role and future applications. <i>Nature Reviews Rheumatology</i> , 2017, 13, 503-510.	3.5	51
143	Mortality rates are increased in patients with systemic juvenile idiopathic arthritis. <i>Archives of Disease in Childhood</i> , 2017, 102, 206.2-207.	1.0	14
144	Spectrum of lymphomas across different drug treatment groups in rheumatoid arthritis: a European registries collaborative project. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2025-2030.	0.5	77

#	ARTICLE	IF	CITATIONS
145	A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities. <i>Pediatric Rheumatology</i> , 2017, 15, 31.	0.9	27
146	Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab. <i>Rheumatology</i> , 2017, 56, kew493.	0.9	9
147	Efficacy of biologic therapy across individual juvenile idiopathic arthritis subtypes: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 584-593.	1.6	37
148	Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-“Tumor Necrosis Factor. <i>Arthritis Care and Research</i> , 2017, 69, 783-793.	1.5	32
149	159.â€fTHE IMPORTANCE OF ACHIEVING CLINICAL RESPONSE TO TREATMENT AND CHANGES IN PHYSICAL ABILITY AND QUALITY OF LIFE ON WORKER PRODUCTIVITY OUTCOMES IN RHEUMATOID ARTHRITIS: RESULTS FROM THE BRITISH SOCIETY FOR RHEUMATOLOGY BIOLOGICS REGISTER FOR RHEUMATOID ARTHRITIS. <i>Rheumatology</i> , 2017, 56, .	0.9	0
150	Response to: “Does the risk of lymphoma in patients with RA treated with TNF inhibitors differ according to the histological subtype and the type of TNF inhibitor?”â€™ by Nocturne et al. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, e4-e4.	0.5	2
151	054.â€fTREATMENT DECISIONS FOLLOWING A DIAGNOSIS OF CANCER DURING TUMUOR NECROSIS FACTOR INHIBITOR TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS. <i>Rheumatology</i> , 2017, 56, .	0.9	0
152	The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. <i>Rheumatology</i> , 2017, 56, kew387.	0.9	10
153	49.â€fBiological treatments for adults with Juvenile Idiopathic Arthritis: a clear need for improved access to targeted education and training. <i>Rheumatology</i> , 2017, 56, .	0.9	0
154	177.â€fQUALITY VERSUS FRAUD IN CLINICAL RESEARCH: HOW RESEARCH METHODOLOGY CAN INFLUENCE RESEARCH CONCLUSIONS. <i>Rheumatology</i> , 2017, 56, .	0.9	0
155	Effectiveness and safety of TNF inhibitors in adults with juvenile idiopathic arthritis. <i>RMD Open</i> , 2016, 2, e000273.	1.8	8
156	Psychological factors predict adherence to methotrexate in rheumatoid arthritis; findings from a systematic review of rates, predictors and associations with patient-reported and clinical outcomes. <i>RMD Open</i> , 2016, 2, e000171.	1.8	40
157	Trends in paediatric rheumatology referral times and disease activity indices over a ten-year period among children and young people with Juvenile Idiopathic Arthritis: results from the childhood arthritis prospective Study. <i>Rheumatology</i> , 2016, 55, 1225-1234.	0.9	54
158	Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. <i>Rheumatology</i> , 2016, 55, 840-847.	0.9	33
159	Risk of<i>Pneumocystis jirovecii</i> pneumonia in patients with rheumatoid arthritis treated with inhibitors of tumour necrosis factor I±: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis: Table 1. <i>Rheumatology</i> , 2016, 55, 1336-1337.	0.9	15
160	The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis. <i>Rheumatology</i> , 2016, 55, 2033-2039.	0.9	67
161	Association Between Ischemic Stroke and Tumor Necrosis Factor Inhibitor Therapy in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1337-1345.	2.9	16
162	Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1353-1360.	2.9	59

#	ARTICLE	IF	CITATIONS
163	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. <i>Rheumatology</i> , 2016, 55, 2050-2055.	0.9	14
164	Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature. <i>Arthritis Research and Therapy</i> , 2016, 18, 251.	1.6	177
165	What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2016, 18, 282.	1.6	21
166	The BSRBR-RA at 15 years. <i>Rheumatology</i> , 2016, 55, 2093-2095.	0.9	11
167	Treatment prescribing patterns in patients with juvenile idiopathic arthritis (JIA): Analysis from the UK Childhood Arthritis Prospective Study (CAPS). <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 190-195.	1.6	23
168	Previously reported <i>SLCO1C1</i> genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. <i>Pharmacogenomics</i> , 2016, 17, 715-720.	0.6	9
169	Factors associated with choice of biologic among children with Juvenile Idiopathic Arthritis: results from two UK paediatric biologic registers. <i>Rheumatology</i> , 2016, 55, 1556-1565.	0.9	38
170	Influence of past breast feeding on pattern and severity of presentation of juvenile idiopathic arthritis. <i>Archives of Disease in Childhood</i> , 2016, 101, 348-351.	1.0	26
171	Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 2487-2494.	2.9	45
172	Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. <i>Arthritis Research and Therapy</i> , 2015, 17, 359.	1.6	6
173	Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and Registers. <i>Arthritis Care and Research</i> , 2015, 67, 1219-1229.	1.5	20
174	PP3. Standardized mortality rates are increased in patients with severe JIA. <i>Rheumatology</i> , 2015, 54, ii6-ii6.	0.9	2
175	274. Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from Two UK Paediatric Biologic Registers. <i>Rheumatology</i> , 2015, .	0.9	0
176	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. <i>Rheumatology</i> , 2015, 54, 1074-1079.	0.9	22
177	The Association Between Low Socioeconomic Status With High Physical Limitations and Low Illness Self-Perception in Patients With Juvenile Idiopathic Arthritis: Results From the Childhood Arthritis Prospective Study. <i>Arthritis Care and Research</i> , 2015, 67, 382-389.	1.5	23
178	<i>HLA-DRB1*11</i> and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15970-15975.	3.3	139
179	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Rheumatology</i> , 2015, 54, 494-499.	0.9	90
180	O10. Risk and Characteristics of Drug-Induced Lupus in Patients Exposed to Tumour Necrosis Factor- β Inhibitor Therapy: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Rheumatology</i> , 2015, .	0.9	0

#	ARTICLE	IF	CITATIONS
181	Association of HLA-DRB1 Haplotypes With Rheumatoid Arthritis Severity, Mortality, and Treatment Response. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1645.	3.8	119
182	Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1087-1093.	0.5	162
183	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , 2015, 385, S48.	6.3	18
184	Growth in children and adolescents with juvenile idiopathic arthritis over 2 years of treatment with etanercept: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study. <i>Rheumatology</i> , 2015, 54, 1279-1285.	0.9	11
185	The influence of behavioural and psychological factors on medication adherence over time in rheumatoid arthritis patients: a study in the biologics era. <i>Rheumatology</i> , 2015, 54, 1780-1791.	0.9	69
186	P2.â€fIncidence and Severity of Myocardial Infarction in Subjects Receiving Anti-Tumour Necrosis Factor Drugs for Rheumatoid Arthritis: Results from Linking the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and Myocardial Ischaemia National Audit Project. <i>Rheumatology</i> , 2014, 53, i34-i35.	0.9	4
187	O23.â€fThe Influence of Anti-TNF or Rituximab on Cancer Incidence in Patients with Rheumatoid Arthritis who Have Had a Prior Malignancy. <i>Rheumatology</i> , 2014, 53, i38-i38.	0.9	0
188	39.â€fNon-Differential Reporting of Myocardial Infarction to a National Observational Drug Safety Study Using Linked Data: Linkage of the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis and the Myocardial Ischaemia National Audit Project. <i>Rheumatology</i> , 2014, 53, i70-i70.	0.9	0
189	Biologic therapies and pregnancy: the story so far. <i>Rheumatology</i> , 2014, 53, 1377-1385.	0.9	99
190	When TNF inhibitors fail in RAâ€”weighing up the options. <i>Nature Reviews Rheumatology</i> , 2014, 10, 262-264.	3.5	8
191	Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 229-234.	0.5	146
192	Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. <i>Rheumatology</i> , 2013, 52, 91-98.	0.9	116
193	Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis. <i>PLoS Genetics</i> , 2013, 9, e1003394.	1.5	146
194	Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 143-144.	0.5	30
195	Biologic treatment response among adults with juvenile idiopathic arthritis: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2013, 52, 1905-1913.	0.9	30
196	Recent developments in disease activity indices and outcome measures for juvenile idiopathic arthritis. <i>Rheumatology</i> , 2013, 52, 1941-1951.	0.9	27
197	Validity of a three-variable Juvenile Arthritis Disease Activity Score in children with new-onset juvenile idiopathic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1983-1988.	0.5	126
198	The incidence of rheumatoid arthritis in the UK: comparisons using the 2010 ACR/EULAR classification criteria and the 1987 ACR classification criteria. Results from the Norfolk Arthritis Register. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1315-1320.	0.5	116

#	ARTICLE	IF	CITATIONS
199	Influence of anti-TNF patient warning regarding avoidance of high risk foods on rates of listeria and salmonella infections in the UK. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 461-462.	0.5	33
200	Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register. <i>Journal of Rheumatology</i> , 2012, 39, 240-246.	1.0	67
201	Abatacept in the long-term treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2012, 8, 231-234.	1.3	5
202	Juvenile-onset inflammatory arthritis: a study of adolescents' beliefs about underlying cause. <i>Rheumatology</i> , 2012, 51, 2239-2245.	0.9	4
203	Prediction of response and adverse events to methotrexate treatment in patients with rheumatoid arthritis. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 559-567.	0.3	5
204	The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 869-874.	0.5	107
205	Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. <i>Arthritis Care and Research</i> , 2012, 64, 1108-1115.	1.5	81
206	Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. <i>Rheumatology</i> , 2011, 50, 124-131.	0.9	564
207	Agreement between Proxy and Adolescent Assessment of Disability, Pain, and Well-Being in Juvenile Idiopathic Arthritis. <i>Journal of Pediatrics</i> , 2011, 158, 307-312.	0.9	33
208	Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. <i>Arthritis and Rheumatism</i> , 2011, 63, 645-653.	6.7	143
209	Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 583-589.	0.5	188
210	Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 823-826.	0.5	154
211	Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumor necrosis factor therapy for rheumatoid arthritis between 2001 and 2008. <i>Rheumatology</i> , 2011, 50, 117-123.	0.9	77
212	Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients. <i>Rheumatology</i> , 2011, 50, 189-195.	0.9	62
213	Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1831-1834.	0.5	62
214	Detection and evaluation of a drug safety signal concerning pancreatic cancer: lessons from a joint approach of three European biologics registers. <i>Rheumatology</i> , 2011, 50, 146-151.	0.9	18
215	Rheumatoid arthritis risk allele <i>PTPRC</i> is also associated with response to anti-tumor necrosis factor therapy. <i>Arthritis and Rheumatism</i> , 2010, 62, 1849-1861.	6.7	95
216	No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. <i>Arthritis and Rheumatism</i> , 2010, 62, 3145-3153.	6.7	72

#	ARTICLE	IF	CITATIONS
217	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. <i>Rheumatology</i> , 2010, 49, 1197-1199.	0.9	49
218	Disease activity and disability in children with juvenile idiopathic arthritis one year following presentation to paediatric rheumatology. Results from the Childhood Arthritis Prospective Study. <i>Rheumatology</i> , 2010, 49, 116-122.	0.9	86
219	Comment on: Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register: reply. <i>Rheumatology</i> , 2010, 49, 1794-1794.	0.9	0
220	Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2010, 49, 697-705.	0.9	112
221	BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. <i>Rheumatology</i> , 2010, 49, 2217-2219.	0.9	187
222	Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. <i>Rheumatology</i> , 2010, 49, 1570-1577.	0.9	73
223	BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. <i>Rheumatology</i> , 2010, , .	0.9	1
224	Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification. <i>American Journal of Epidemiology</i> , 2009, 169, 909-917.	1.6	71
225	Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. <i>Rheumatology</i> , 2009, 48, 1323-1327.	0.9	50
226	Biologic Therapy for Rheumatoid Arthritis. <i>BioDrugs</i> , 2009, 23, 111-124.	2.2	75
227	Persistence with anti-tumor necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. <i>Arthritis Research and Therapy</i> , 2009, 11, R52.	1.6	173
228	Patients with suspected rheumatoid arthritis should be referred early to rheumatology. <i>BMJ: British Medical Journal</i> , 2008, 336, 215-216.	2.4	24
229	Are patients with RA at increased risk of malignancy?. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 632-633.	3.2	1
230	Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. <i>Rheumatology</i> , 2008, 47, 1000-1005.	0.9	67
231	Outcomes after switching from one anti-tumor necrosis factor \pm agent to a second anti-tumor necrosis factor \pm agent in patients with rheumatoid arthritis: Results from a large UK national cohort study. <i>Arthritis and Rheumatism</i> , 2007, 56, 13-20.	6.7	379
232	Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. <i>Arthritis and Rheumatism</i> , 2006, 54, 1786-1794.	6.7	136
233	Assessing the safety of biologic therapies in rheumatoid arthritis: the challenges of study design. <i>Journal of rheumatology Supplement, The</i> , 2005, 72, 48-50.	2.2	7
234	The role of the British society for rheumatology biologics register (BSRBR) and the NICE guidelines for anti - TNF therapy. <i>Musculoskeletal Care</i> , 2003, 1, 58-64.	0.6	11

#	ARTICLE	IF	CITATIONS
235	221.â€fRisk of Cancer in Patients with Severe Psoriatic Arthritis Requiring Tumour Necrosis Factor Alpha Inhibition. Rheumatology, 0, , .	0.9	0
236	220.â€fPredicting Successful Long-Term Treatment with Tumour Necrosis Factor Alpha Inhibitors in Patients with Psoriatic Arthritis. Rheumatology, 0, , .	0.9	0
237	032â€fEstimates of Inactive Disease are Strongly Influenced by Outcome Definition in a Prospective Cohort of Patients with Juvenile Idiopathic Arthritis. Rheumatology, 0, , .	0.9	0
238	050â€fHigh Frequency of Anti-Drug Antibodies and Correlation of Low Random Drug Levels with Lack of Efficacy in Certolizumab Pegol-Treated Patients with Rheumatoid Arthritis. Rheumatology, 0, , .	0.9	0
239	Is time a healer? How quality of life changes over time reported by parents of children and young people with Juvenile Idiopathic Arthritis. Rheumatology, 0, , .	0.9	0